245 related articles for article (PubMed ID: 31930364)
1. Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial.
Isaacson SH; Ondo W; Jackson CE; Trosch RM; Molho E; Pagan F; Lew M; Dashtipour K; Clinch T; Espay AJ;
JAMA Neurol; 2020 Apr; 77(4):461-469. PubMed ID: 31930364
[TBL] [Abstract][Full Text] [Related]
2. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks.
Jost WH; Friedman A; Michel O; Oehlwein C; Slawek J; Bogucki A; Ochudlo S; Banach M; Pagan F; Flatau-Baqué B; Dorsch U; Csikós J; Blitzer A
Parkinsonism Relat Disord; 2020 Jan; 70():23-30. PubMed ID: 31794936
[TBL] [Abstract][Full Text] [Related]
3. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.
Jost WH; Friedman A; Michel O; Oehlwein C; Slawek J; Bogucki A; Ochudlo S; Banach M; Pagan F; Flatau-Baqué B; Csikós J; Cairney CJ; Blitzer A
Neurology; 2019 Apr; 92(17):e1982-e1991. PubMed ID: 30918101
[TBL] [Abstract][Full Text] [Related]
4. Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview.
Petracca M; Guidubaldi A; Ricciardi L; Ialongo T; Del Grande A; Mulas D; Di Stasio E; Bentivoglio AR
Toxicon; 2015 Dec; 107(Pt A):129-40. PubMed ID: 26327120
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.
Chinnapongse R; Gullo K; Nemeth P; Zhang Y; Griggs L
Mov Disord; 2012 Feb; 27(2):219-26. PubMed ID: 21887710
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.
Gracies JM; Brashear A; Jech R; McAllister P; Banach M; Valkovic P; Walker H; Marciniak C; Deltombe T; Skoromets A; Khatkova S; Edgley S; Gul F; Catus F; De Fer BB; Vilain C; Picaut P;
Lancet Neurol; 2015 Oct; 14(10):992-1001. PubMed ID: 26318836
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension.
Gracies JM; Esquenazi A; Brashear A; Banach M; Kocer S; Jech R; Khatkova S; Benetin J; Vecchio M; McAllister P; Ilkowski J; Ochudlo S; Catus F; Grandoulier AS; Vilain C; Picaut P;
Neurology; 2017 Nov; 89(22):2245-2253. PubMed ID: 29093068
[TBL] [Abstract][Full Text] [Related]
8. Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI.
Berweck S; Bonikowski M; Kim H; Althaus M; Flatau-Baqué B; Mueller D; Banach MD
Neurology; 2021 Oct; 97(14):e1425-e1436. PubMed ID: 34341153
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin A for children with salivary control problems.
Montgomery J; McCusker S; Hendry J; Lumley E; Kubba H
Int J Pediatr Otorhinolaryngol; 2014 Nov; 78(11):1970-3. PubMed ID: 25242701
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a systematic review and meta-analysis.
Yang CL; Huang JP; Tan YC; Wang TT; Zhang H; Qu Y
BMC Pharmacol Toxicol; 2023 Oct; 24(1):52. PubMed ID: 37828600
[TBL] [Abstract][Full Text] [Related]
11. A Double-Blind Randomized Controlled Trial Investigating the Most Efficacious Dose of Botulinum Toxin-A for Sialorrhea Treatment in Asian Adults with Neurological Diseases.
Mazlan M; Rajasegaran S; Engkasan JP; Nawawi O; Goh KJ; Freddy SJ
Toxins (Basel); 2015 Sep; 7(9):3758-70. PubMed ID: 26402703
[TBL] [Abstract][Full Text] [Related]
12. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease.
Ondo WG; Hunter C; Moore W
Neurology; 2004 Jan; 62(1):37-40. PubMed ID: 14718694
[TBL] [Abstract][Full Text] [Related]
13. Association of onabotulinum toxin A treatment with salivary pH and dental caries of neurologically impaired children with sialorrhea.
Ferraz Dos Santos B; Dabbagh B; Daniel SJ; Schwartz S
Int J Paediatr Dent; 2016 Jan; 26(1):45-51. PubMed ID: 25726732
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia.
McVary KT; Roehrborn CG; Chartier-Kastler E; Efros M; Bugarin D; Chen R; Patel A; Haag-Molkenteller C
J Urol; 2014 Jul; 192(1):150-6. PubMed ID: 24508634
[TBL] [Abstract][Full Text] [Related]
15. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P
Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease.
Guidubaldi A; Fasano A; Ialongo T; Piano C; Pompili M; Mascianà R; Siciliani L; Sabatelli M; Bentivoglio AR
Mov Disord; 2011 Feb; 26(2):313-9. PubMed ID: 21259343
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type A therapy for cervical dystonia.
Castelão M; Marques RE; Duarte GS; Rodrigues FB; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003633. PubMed ID: 29230798
[TBL] [Abstract][Full Text] [Related]
19. A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients.
Jost WH; Steffen A; Berweck S
Expert Rev Neurother; 2021 Oct; 21(10):1059-1068. PubMed ID: 34516331
[TBL] [Abstract][Full Text] [Related]
20. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders.
Naumann M; Dressler D; Hallett M; Jankovic J; Schiavo G; Segal KR; Truong D
Toxicon; 2013 Jun; 67():141-52. PubMed ID: 23178324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
